Get the Stockscreener App
0.264
3.13%
0.008
After Hours:
.26
-0.004
-1.52%
Vincerx Pharma Inc stock is traded at $0.264, with a volume of 145.02K.
It is up +3.13% in the last 24 hours and down -30.53% over the past month.
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.
See More
Previous Close:
$0.256
Open:
$0.2573
24h Volume:
145.02K
Relative Volume:
0.29
Market Cap:
$8.41M
Revenue:
-
Net Income/Loss:
$-48.85M
P/E Ratio:
-0.0996
EPS:
-2.65
Net Cash Flow:
$-46.25M
1W Performance:
-4.21%
1M Performance:
-30.53%
6M Performance:
-61.39%
1Y Performance:
-60.99%
1-Day Range:
$0.25
$0.2799
1-Week Range:
$0.2425
$0.2799
52-Week Range:
$0.2425
$9.3722
Vincerx Pharma Inc Stock (VINC) Company Profile
Name
Vincerx Pharma Inc
Sector
Industry
Phone
650-800-6676
Address
260 SHERIDAN AVENUE, PALO ALTO
Compare VINC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VINC
Vincerx Pharma Inc
|
0.264 | 8.41M | 0 | -48.85M | -46.25M | -2.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Vincerx Pharma Inc Stock (VINC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-14-22 | Initiated | H.C. Wainwright | Buy |
| Dec-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-21 | Initiated | SVB Leerink | Outperform |
| Sep-13-21 | Initiated | Laidlaw | Buy |
| Aug-25-21 | Initiated | B. Riley Securities | Buy |
Vincerx Pharma Inc Stock (VINC) Latest News
Vincerx Pharma gets extension to meet Nasdaq listing criteria - Investing.com
Vincerx Pharma gets extension to meet Nasdaq listing criteria By Investing.com - Investing.com UK
Leerink Partnrs Weighs in on Vincerx Pharma FY2024 Earnings - Defense World
ARMISTICE CAPITAL, LLC Expands Stake in Vincerx Pharma Inc - GuruFocus.com
Vincerx Pharma Inc (VINC) Quarterly 10-Q Report - Quartzy
Prosight Management, LP Reduces Stake in Vincerx Pharma Inc - GuruFocus.com
Vincerx Pharma Reports Q3 2024 Financial Results - TipRanks
Vincerx Pharma Inc reports results for the quarter ended September 30Earnings Summary - XM
Vincerx Pharma Reports Third Quarter 2024 Financial Results - GlobeNewswire
Vincerx Pharma Reports Complete Responses in VIP943 Trial, Narrows Q3 Loss to $0.17/Share | VINC Stock News - StockTitan
VINC stock touches 52-week low at $0.32 amid market challenges - Investing.com Canada
SEC Form PRE 14A filed by Vincerx Pharma Inc. - Quantisnow
VINC Stock on the Rise: A Promising Investment - The InvestChronicle
Should investors be concerned about Vincerx Pharma Inc (VINC)? - US Post News
Financial Health Check: Examining Vincerx Pharma Inc (VINC)’s Key Ratios - The Dwinnex
What Makes Vincerx Pharma (VINC) a New Buy Stock - Yahoo Finance
Check Out Vincerx Pharma Inc (VINC)’s Trade Data Rather Than the Analysts’ Views - SETE News
Taking a Closer Look At Vincerx Pharma Inc (VINC) Following Its Recent Trade - Knox Daily
VINC Stock Touches 52-Week Low at $0.51 Amid Market Challenges By Investing.com - Investing.com South Africa
VINC Stock Touches 52-Week Low at $0.51 Amid Market Challenges - Investing.com
Wall Street Analyst Initiated Vincerx Pharma Inc [VINC]. What else is Wall St. saying - The DBT News
Vincerx stock tumbles 20% on corporate updates - MSN
Vincerx Pharma Inc (VINC) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Leerink Partners Cuts Vincerx Pharma (NASDAQ:VINC) Price Target to $2.00 - Defense World
Vincerx reports two complete responses in VIP943 study By Investing.com - Investing.com Australia
VINC’s price-to-cash ratio: Is it a good investment at the moment? - US Post News
Vincerx stock tumbles 20% on corporate updates (NASDAQ:VINC) - Seeking Alpha
Leerink cuts Vincerx Pharma stock target on pipeline update By Investing.com - Investing.com UK
Financial Fitness Check: Examining Vincerx Pharma Inc (VINC)’s Key Ratios - The Dwinnex
Vincerx reports two complete responses in VIP943 study - Investing.com
Vincerx Reports Positive Initial Clinical Data from Ongoing - GlobeNewswire
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates - StockTitan
Why Is Cancer Focused Penny Stock Vincerx Pharma Trading Higher Today? - MSN
Vincerx Pharma (NASDAQ:VINC) Trading Down 2.1% - Defense World
A better buy-in window may exist right now for Vincerx Pharma Inc (VINC) - SETE News
Investing in Vincerx Pharma Inc (VINC) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely - Simply Wall St
Companies Like Vincerx Pharma (NASDAQ:VINC) Could Be Quite Risky - Yahoo Finance
Vanguard Group Inc. Has $3.38 Million Position in Vincerx Pharma, Inc. (NASDAQ:VINC) - Defense World
Vincerx Pharma Announces Stock Option Repricing and Shareholder Approval - TipRanks
VINC Stock Earnings: Vincerx Pharma Beats EPS for Q2 2024 - MSN
Vincerx Pharma Reports Second Quarter 2024 Financial Results - GlobeNewswire
Acadian Asset Management LLC Sells 36,571 Shares of Vincerx Pharma, Inc. (NASDAQ:VINC) - Defense World
Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Decreases By 31.7% - Defense World
How should investors view Vincerx Pharma Inc (VINC)? – US Post News - US Post News
Vincerx Pharma Inc (VINC) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Down 29.3% in June - Defense World
Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts? - Yahoo Finance
Vincerx Pharma Inc Inc. (VINC) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Vincerx Pharma (VINC) Moves to Buy: Rationale Behind the Upgrade - MSN
Vincerx Pharma (NASDAQ:VINC) Trading Down 7.1% - Defense World
Vincerx Pharma Inc Stock (VINC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):